Zacks Investment Research
26 Jun 2026, 22:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
CRISPR Therapeutics AG (CRSP) is projected to report quarterly revenue of $7.42 million, a 733.26% increase over the prior year. — Significant revenue growth suggests strong commercial scaling or milestone payments, which is a positive catalyst for a biotech firm.
+0.40Full-year revenue estimates for CRISPR Therapeutics AG are projected to grow by 722.82% compared to the previous year. — Sustained high growth expectations for the full year indicate a positive long-term trajectory for the company's business model.
+0.30The Zacks Consensus EPS estimate for CRISPR Therapeutics AG has shifted 1.47% upward over the past month. — Positive analyst revisions generally correlate with short-term price appreciation, though the magnitude here is modest.
+0.15Continue reading
6 related stories
Top 2 movers · tap to explore
The Medical - Biomedical and Genetics industry currently ranks in the bottom 39% of all industries according to Zacks Industry Rank. — Broad industry weakness suggests systemic headwinds or lack of relative strength for companies in this specific sector.
-0.10Which stocks this story touches
The company showed a positive daily price change, outpaced major indices, and is projecting significant year-over-year revenue growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
